Dr Danielle Meyrick (Chief Scientific Officer) & A/Prof Nat Lenzo (Medical Director) recently published an article titled “PSMA | Prostate Cancer Theranostics” for the Prostate Cancer Research Institute (PCRI). Read Here >>> https://goo.gl/sLukvS
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the 2018 Image of the Year was awarded to PMCC, Melbourne, Australia. Read More >> https://goo.gl/YjbHyA
The Clinical Oncology Society of Australia (COSA) has recently published a position statement on Exercise in Cancer Care. COSA has called for “exercise to be embedded as part of standard practice in cancer care and to be viewed as an adjunct therapy that helps counteract the adverse effects of cancer and its treatment.” Read More >>https://goo.gl/r2R3MK
PATIENT POV – The Sydney Morning Herald also published an article about Lutetium-177 PSMA therapy, interviewing a 76yo patient who “had exhausted all conventional treatments but one”. Read More>>> https://goo.gl/otq3ST
MEN’S HEALTH – The Australian Financial Review has recently published an article about Lutetium-177 PSMA therapy, a theranostics approach to treating mCRPC. Read More>>> https://goo.gl/BPgcvQ
Congratulations to the #WFNMB and all parties involved in the success of the 12th World Congress of the World Federation of Nuclear Medicine & Biology in Melbourne, Australia. We look forward to the 13th World Congress of the WFNMB to be hosted in Kyoto, Japan (2022).
Theranostics Australia’s Dr. Danielle Meyrick (Chief Scientific Officer) displayed TWO abstract submissions as posters yesterday in the Exhibition Hall at the #WFNMB2018 Conference.
(3) 68Ga-PSMA-PET/CT is Superior to Contrast CT in Rising PSA Post Definitive Treatment for Prostate Cancer (P140).
(4) Initial Experience with 1 year Follow Up in 22 Patients Treated with Lu-177 I&T PSMA for Advanced Prostate Cancer – Safety, Efficacy and Quality of Life (P199).
All 4 of TA’s posters from the WFNMB Conference will be made available this week.
For delegates attending the #WFNMB2018 Conference, Theranostics Australia will be displaying 2 abstract submissions as posters today in the Exhibition Hall.
(1) Australian Two Centre Experience in First 150 Patients Using 68Ga Based Kit for the Production of 68Ga-PSMA-11 (P194).
(2) Incidental Treatment of Mycobacterium Avium Complex (MAC) Infection with 131Iodine (P064).
Theranostics Australia would like to thank all 170+ delegates who attended our successful breakfast session this morning at the #WFNMB2018 Conference in Melbourne, as well as our invited speakers Prof Dale Bailey, Prof Kate Vallis, Dr Matt Harris and Dr Danielle Meyrick. We hope you enjoy the remainder of the #WFNMB2018 Conference.
Theranostics Australia would like to congratulate Prof Harvey Turner on his Pioneer Lecture “Global harmonization of clinical practice of theranostic nuclear oncology” presented at the #WFNMB2018 for the Australian and New Zealand Society of Nuclear Medicine (ANZSNM).
